Loading…

Activation-inducible CAR expression enables precise control over engineered CAR T cell function

CAR T cell therapy is a rapidly growing area of oncological treatments having a potential of becoming standard care for multiple indications. Coincidently, CRISPR/Cas gene-editing technology is entering next-generation CAR T cell product manufacturing with the promise of more precise and more contro...

Full description

Saved in:
Bibliographic Details
Published in:Communications biology 2023-06, Vol.6 (1), p.604-604, Article 604
Main Authors: Fraessle, Simon P., Tschulik, Claudia, Effenberger, Manuel, Cletiu, Vlad, Gerget, Maria, Schober, Kilian, Busch, Dirk H., Germeroth, Lothar, Stemberger, Christian, Poltorak, Mateusz P.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c541t-6533b97083c32f59a7c76cc39af266bd0586b2eddaacb330d834a32f42b3effc3
cites cdi_FETCH-LOGICAL-c541t-6533b97083c32f59a7c76cc39af266bd0586b2eddaacb330d834a32f42b3effc3
container_end_page 604
container_issue 1
container_start_page 604
container_title Communications biology
container_volume 6
creator Fraessle, Simon P.
Tschulik, Claudia
Effenberger, Manuel
Cletiu, Vlad
Gerget, Maria
Schober, Kilian
Busch, Dirk H.
Germeroth, Lothar
Stemberger, Christian
Poltorak, Mateusz P.
description CAR T cell therapy is a rapidly growing area of oncological treatments having a potential of becoming standard care for multiple indications. Coincidently, CRISPR/Cas gene-editing technology is entering next-generation CAR T cell product manufacturing with the promise of more precise and more controllable cell modification methodology. The intersection of these medical and molecular advancements creates an opportunity for completely new ways of designing engineered cells to help overcome current limitations of cell therapy. In this manuscript we present proof-of-concept data for an engineered feedback loop. We manufactured activation-inducible CAR T cells with the help of CRISPR-mediated targeted integration. This new type of engineered T cells expresses the CAR gene dependent on their activation status. This artifice opens new possibilities to regulate CAR T cell function both in vitro and in vivo. We believe that such a physiological control system can be a powerful addition to the currently available toolbox of next-generation CAR constructs. T cells are modified to express the CAR gene dependent on activation status under the control of an engineered feedback loop and are shown to function in vitro and in vivo to kill tumour cells.
doi_str_mv 10.1038/s42003-023-04978-w
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4cff20855bed40668525e3196d9e0810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4cff20855bed40668525e3196d9e0810</doaj_id><sourcerecordid>2822567699</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-6533b97083c32f59a7c76cc39af266bd0586b2eddaacb330d834a32f42b3effc3</originalsourceid><addsrcrecordid>eNp9ksFu1DAQhi0EotXSF-CAInHhEnA8tmOf0GpFS6VKSKicLceZLF5l48VOtvD2OJtSWg4cLFvzf_PbMx5CXlf0fUVBfUicUQolZXlxXavy7hk5Z6B1CZKz54_OZ-QipR2ltNJaS-AvyRnUrK45wDkxazf6ox19GEo_tJPzTY_FZv21wJ-HiCllocDB5mgqcsD5hIULwxhDX4Qjxixu_YAYsT2l3RYO-77opsHNpq_Ii872CS_u9xX5dvnpdvO5vPlydb1Z35RO8GospQBodE0VOGCd0LZ2tXQOtO2YlE1LhZINw7a11jUAtFXAbSY5awC7zsGKXC--bbA7c4h-b-MvE6w3p0CIW2Pj6F2PhruuY1QJ0WDLqZRKMIFQadlqpCo3d0U-Ll6Hqdlj6zBXa_snpk-VwX8323A0FWW8UlRkh3f3DjH8mDCNZu_T3Bc7YJiSYYoB5bRSOqNv_0F3YYpD7tVMMSFrqWeKLZSLIaWI3cNrKmrmeTDLPJg8D-Y0D-YuJ715XMdDyp_fzwAsQMrSsMX49-7_2P4G0n_BSQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2822567699</pqid></control><display><type>article</type><title>Activation-inducible CAR expression enables precise control over engineered CAR T cell function</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Fraessle, Simon P. ; Tschulik, Claudia ; Effenberger, Manuel ; Cletiu, Vlad ; Gerget, Maria ; Schober, Kilian ; Busch, Dirk H. ; Germeroth, Lothar ; Stemberger, Christian ; Poltorak, Mateusz P.</creator><creatorcontrib>Fraessle, Simon P. ; Tschulik, Claudia ; Effenberger, Manuel ; Cletiu, Vlad ; Gerget, Maria ; Schober, Kilian ; Busch, Dirk H. ; Germeroth, Lothar ; Stemberger, Christian ; Poltorak, Mateusz P.</creatorcontrib><description>CAR T cell therapy is a rapidly growing area of oncological treatments having a potential of becoming standard care for multiple indications. Coincidently, CRISPR/Cas gene-editing technology is entering next-generation CAR T cell product manufacturing with the promise of more precise and more controllable cell modification methodology. The intersection of these medical and molecular advancements creates an opportunity for completely new ways of designing engineered cells to help overcome current limitations of cell therapy. In this manuscript we present proof-of-concept data for an engineered feedback loop. We manufactured activation-inducible CAR T cells with the help of CRISPR-mediated targeted integration. This new type of engineered T cells expresses the CAR gene dependent on their activation status. This artifice opens new possibilities to regulate CAR T cell function both in vitro and in vivo. We believe that such a physiological control system can be a powerful addition to the currently available toolbox of next-generation CAR constructs. T cells are modified to express the CAR gene dependent on activation status under the control of an engineered feedback loop and are shown to function in vitro and in vivo to kill tumour cells.</description><identifier>ISSN: 2399-3642</identifier><identifier>EISSN: 2399-3642</identifier><identifier>DOI: 10.1038/s42003-023-04978-w</identifier><identifier>PMID: 37277433</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/31 ; 42/41 ; 59/5 ; 631/250/251 ; 631/61/2300/1851 ; 631/61/24 ; Biology ; Biomedical and Life Sciences ; CAR gene ; Cell activation ; Cell therapy ; Cellular apoptosis susceptibility protein ; CRISPR ; CRISPR-Cas Systems ; Feedback ; Gene Editing - methods ; Immunotherapy, Adoptive - methods ; Life Sciences ; Lymphocytes ; Lymphocytes T ; Receptors, Chimeric Antigen - genetics ; Receptors, Chimeric Antigen - metabolism ; T-Lymphocytes - metabolism</subject><ispartof>Communications biology, 2023-06, Vol.6 (1), p.604-604, Article 604</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-6533b97083c32f59a7c76cc39af266bd0586b2eddaacb330d834a32f42b3effc3</citedby><cites>FETCH-LOGICAL-c541t-6533b97083c32f59a7c76cc39af266bd0586b2eddaacb330d834a32f42b3effc3</cites><orcidid>0000-0001-9323-9472 ; 0009-0009-5821-3280 ; 0000-0001-8713-093X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241805/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2822567699?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37277433$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fraessle, Simon P.</creatorcontrib><creatorcontrib>Tschulik, Claudia</creatorcontrib><creatorcontrib>Effenberger, Manuel</creatorcontrib><creatorcontrib>Cletiu, Vlad</creatorcontrib><creatorcontrib>Gerget, Maria</creatorcontrib><creatorcontrib>Schober, Kilian</creatorcontrib><creatorcontrib>Busch, Dirk H.</creatorcontrib><creatorcontrib>Germeroth, Lothar</creatorcontrib><creatorcontrib>Stemberger, Christian</creatorcontrib><creatorcontrib>Poltorak, Mateusz P.</creatorcontrib><title>Activation-inducible CAR expression enables precise control over engineered CAR T cell function</title><title>Communications biology</title><addtitle>Commun Biol</addtitle><addtitle>Commun Biol</addtitle><description>CAR T cell therapy is a rapidly growing area of oncological treatments having a potential of becoming standard care for multiple indications. Coincidently, CRISPR/Cas gene-editing technology is entering next-generation CAR T cell product manufacturing with the promise of more precise and more controllable cell modification methodology. The intersection of these medical and molecular advancements creates an opportunity for completely new ways of designing engineered cells to help overcome current limitations of cell therapy. In this manuscript we present proof-of-concept data for an engineered feedback loop. We manufactured activation-inducible CAR T cells with the help of CRISPR-mediated targeted integration. This new type of engineered T cells expresses the CAR gene dependent on their activation status. This artifice opens new possibilities to regulate CAR T cell function both in vitro and in vivo. We believe that such a physiological control system can be a powerful addition to the currently available toolbox of next-generation CAR constructs. T cells are modified to express the CAR gene dependent on activation status under the control of an engineered feedback loop and are shown to function in vitro and in vivo to kill tumour cells.</description><subject>13/31</subject><subject>42/41</subject><subject>59/5</subject><subject>631/250/251</subject><subject>631/61/2300/1851</subject><subject>631/61/24</subject><subject>Biology</subject><subject>Biomedical and Life Sciences</subject><subject>CAR gene</subject><subject>Cell activation</subject><subject>Cell therapy</subject><subject>Cellular apoptosis susceptibility protein</subject><subject>CRISPR</subject><subject>CRISPR-Cas Systems</subject><subject>Feedback</subject><subject>Gene Editing - methods</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Life Sciences</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Receptors, Chimeric Antigen - genetics</subject><subject>Receptors, Chimeric Antigen - metabolism</subject><subject>T-Lymphocytes - metabolism</subject><issn>2399-3642</issn><issn>2399-3642</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ksFu1DAQhi0EotXSF-CAInHhEnA8tmOf0GpFS6VKSKicLceZLF5l48VOtvD2OJtSWg4cLFvzf_PbMx5CXlf0fUVBfUicUQolZXlxXavy7hk5Z6B1CZKz54_OZ-QipR2ltNJaS-AvyRnUrK45wDkxazf6ox19GEo_tJPzTY_FZv21wJ-HiCllocDB5mgqcsD5hIULwxhDX4Qjxixu_YAYsT2l3RYO-77opsHNpq_Ii872CS_u9xX5dvnpdvO5vPlydb1Z35RO8GospQBodE0VOGCd0LZ2tXQOtO2YlE1LhZINw7a11jUAtFXAbSY5awC7zsGKXC--bbA7c4h-b-MvE6w3p0CIW2Pj6F2PhruuY1QJ0WDLqZRKMIFQadlqpCo3d0U-Ll6Hqdlj6zBXa_snpk-VwX8323A0FWW8UlRkh3f3DjH8mDCNZu_T3Bc7YJiSYYoB5bRSOqNv_0F3YYpD7tVMMSFrqWeKLZSLIaWI3cNrKmrmeTDLPJg8D-Y0D-YuJ715XMdDyp_fzwAsQMrSsMX49-7_2P4G0n_BSQ</recordid><startdate>20230605</startdate><enddate>20230605</enddate><creator>Fraessle, Simon P.</creator><creator>Tschulik, Claudia</creator><creator>Effenberger, Manuel</creator><creator>Cletiu, Vlad</creator><creator>Gerget, Maria</creator><creator>Schober, Kilian</creator><creator>Busch, Dirk H.</creator><creator>Germeroth, Lothar</creator><creator>Stemberger, Christian</creator><creator>Poltorak, Mateusz P.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9323-9472</orcidid><orcidid>https://orcid.org/0009-0009-5821-3280</orcidid><orcidid>https://orcid.org/0000-0001-8713-093X</orcidid></search><sort><creationdate>20230605</creationdate><title>Activation-inducible CAR expression enables precise control over engineered CAR T cell function</title><author>Fraessle, Simon P. ; Tschulik, Claudia ; Effenberger, Manuel ; Cletiu, Vlad ; Gerget, Maria ; Schober, Kilian ; Busch, Dirk H. ; Germeroth, Lothar ; Stemberger, Christian ; Poltorak, Mateusz P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-6533b97083c32f59a7c76cc39af266bd0586b2eddaacb330d834a32f42b3effc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>13/31</topic><topic>42/41</topic><topic>59/5</topic><topic>631/250/251</topic><topic>631/61/2300/1851</topic><topic>631/61/24</topic><topic>Biology</topic><topic>Biomedical and Life Sciences</topic><topic>CAR gene</topic><topic>Cell activation</topic><topic>Cell therapy</topic><topic>Cellular apoptosis susceptibility protein</topic><topic>CRISPR</topic><topic>CRISPR-Cas Systems</topic><topic>Feedback</topic><topic>Gene Editing - methods</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Life Sciences</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Receptors, Chimeric Antigen - genetics</topic><topic>Receptors, Chimeric Antigen - metabolism</topic><topic>T-Lymphocytes - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fraessle, Simon P.</creatorcontrib><creatorcontrib>Tschulik, Claudia</creatorcontrib><creatorcontrib>Effenberger, Manuel</creatorcontrib><creatorcontrib>Cletiu, Vlad</creatorcontrib><creatorcontrib>Gerget, Maria</creatorcontrib><creatorcontrib>Schober, Kilian</creatorcontrib><creatorcontrib>Busch, Dirk H.</creatorcontrib><creatorcontrib>Germeroth, Lothar</creatorcontrib><creatorcontrib>Stemberger, Christian</creatorcontrib><creatorcontrib>Poltorak, Mateusz P.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Communications biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fraessle, Simon P.</au><au>Tschulik, Claudia</au><au>Effenberger, Manuel</au><au>Cletiu, Vlad</au><au>Gerget, Maria</au><au>Schober, Kilian</au><au>Busch, Dirk H.</au><au>Germeroth, Lothar</au><au>Stemberger, Christian</au><au>Poltorak, Mateusz P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation-inducible CAR expression enables precise control over engineered CAR T cell function</atitle><jtitle>Communications biology</jtitle><stitle>Commun Biol</stitle><addtitle>Commun Biol</addtitle><date>2023-06-05</date><risdate>2023</risdate><volume>6</volume><issue>1</issue><spage>604</spage><epage>604</epage><pages>604-604</pages><artnum>604</artnum><issn>2399-3642</issn><eissn>2399-3642</eissn><abstract>CAR T cell therapy is a rapidly growing area of oncological treatments having a potential of becoming standard care for multiple indications. Coincidently, CRISPR/Cas gene-editing technology is entering next-generation CAR T cell product manufacturing with the promise of more precise and more controllable cell modification methodology. The intersection of these medical and molecular advancements creates an opportunity for completely new ways of designing engineered cells to help overcome current limitations of cell therapy. In this manuscript we present proof-of-concept data for an engineered feedback loop. We manufactured activation-inducible CAR T cells with the help of CRISPR-mediated targeted integration. This new type of engineered T cells expresses the CAR gene dependent on their activation status. This artifice opens new possibilities to regulate CAR T cell function both in vitro and in vivo. We believe that such a physiological control system can be a powerful addition to the currently available toolbox of next-generation CAR constructs. T cells are modified to express the CAR gene dependent on activation status under the control of an engineered feedback loop and are shown to function in vitro and in vivo to kill tumour cells.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>37277433</pmid><doi>10.1038/s42003-023-04978-w</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9323-9472</orcidid><orcidid>https://orcid.org/0009-0009-5821-3280</orcidid><orcidid>https://orcid.org/0000-0001-8713-093X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2399-3642
ispartof Communications biology, 2023-06, Vol.6 (1), p.604-604, Article 604
issn 2399-3642
2399-3642
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_4cff20855bed40668525e3196d9e0810
source Publicly Available Content Database; PubMed Central; Springer Nature - nature.com Journals - Fully Open Access
subjects 13/31
42/41
59/5
631/250/251
631/61/2300/1851
631/61/24
Biology
Biomedical and Life Sciences
CAR gene
Cell activation
Cell therapy
Cellular apoptosis susceptibility protein
CRISPR
CRISPR-Cas Systems
Feedback
Gene Editing - methods
Immunotherapy, Adoptive - methods
Life Sciences
Lymphocytes
Lymphocytes T
Receptors, Chimeric Antigen - genetics
Receptors, Chimeric Antigen - metabolism
T-Lymphocytes - metabolism
title Activation-inducible CAR expression enables precise control over engineered CAR T cell function
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T11%3A16%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation-inducible%20CAR%20expression%20enables%20precise%20control%20over%20engineered%20CAR%20T%20cell%20function&rft.jtitle=Communications%20biology&rft.au=Fraessle,%20Simon%20P.&rft.date=2023-06-05&rft.volume=6&rft.issue=1&rft.spage=604&rft.epage=604&rft.pages=604-604&rft.artnum=604&rft.issn=2399-3642&rft.eissn=2399-3642&rft_id=info:doi/10.1038/s42003-023-04978-w&rft_dat=%3Cproquest_doaj_%3E2822567699%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c541t-6533b97083c32f59a7c76cc39af266bd0586b2eddaacb330d834a32f42b3effc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2822567699&rft_id=info:pmid/37277433&rfr_iscdi=true